| scholarly article | Q13442814 |
| P50 | author | Robert M Bilder | Q56863762 |
| Janet Sinsheimer | Q90679183 | ||
| P2093 | author name string | Paul Shapshak | |
| Elyse J Singer | |||
| Andrew J Levine | |||
| P2860 | cites work | Cognitive neuropsychology of HIV-associated neurocognitive disorders | Q22252615 |
| Cytokines sing the blues: inflammation and the pathogenesis of depression | Q24633065 | ||
| Twenty years of research on cytokine-induced sickness behavior | Q24684760 | ||
| The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density | Q25255374 | ||
| Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia | Q29614929 | ||
| The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function | Q29615582 | ||
| The human immunodeficiency virus reduces network capacity: acoustic noise effect | Q30494107 | ||
| Human immunodeficiency virus dementia: evidence of a subcortical process from studies of fine finger movements | Q30756766 | ||
| Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry | Q31162410 | ||
| Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). | Q33179738 | ||
| COMT Val158Met Polymorphism, Executive Dysfunction, and Sexual Risk Behavior in the Context of HIV Infection and Methamphetamine Dependence | Q33580986 | ||
| Correlation between errors on the Wisconsin Card Sorting Test and the availability of striatal dopamine transporters in healthy volunteers | Q33712203 | ||
| BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization | Q33945215 | ||
| Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China | Q33969552 | ||
| CCL3 genotype and current depression increase risk of HIV-associated dementia | Q34072394 | ||
| HIV dementia: the role of the basal ganglia and dopaminergic systems | Q34098768 | ||
| HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study | Q34370880 | ||
| Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. | Q34402559 | ||
| Parkinsonism in HIV dementia. | Q34732649 | ||
| Catechol O -methyltransferase val 158 -met genotype and individual variation in the brain response to amphetamine | Q35023131 | ||
| Updated research nosology for HIV-associated neurocognitive disorders | Q35755761 | ||
| The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes | Q35860569 | ||
| Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration | Q36302085 | ||
| Two-year prospective study of major depressive disorder in HIV-infected men | Q36808556 | ||
| Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. | Q37031214 | ||
| Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. | Q37152246 | ||
| Role of depression, stress, and trauma in HIV disease progression | Q37180015 | ||
| Epistasis between the DAT 3' UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia | Q37304041 | ||
| Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse | Q37314434 | ||
| Human immunodeficiency virus: infection of the nervous system | Q37881805 | ||
| Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo | Q39309761 | ||
| HIV-1, cocaine, and neuropsychological performance in African American men. | Q39537687 | ||
| Regional quantitative comparison of multispliced to unspliced ratios of HIV-1 RNA copy number in infected human brain | Q40250702 | ||
| HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia | Q41656264 | ||
| HIV dementia and the basal ganglia | Q41693843 | ||
| Severe parkinsonism in two AIDS patients taking prochlorperazine | Q42683842 | ||
| The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease | Q43639344 | ||
| Cerebrovascular changes in the basal ganglia with HIV dementia | Q43723405 | ||
| Striatal dopamine transporters and cognitive functioning in healthy men and women | Q43726221 | ||
| The AIDS dementia complex: I. Clinical features | Q43769670 | ||
| A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition | Q43941587 | ||
| Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. | Q44174109 | ||
| Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia | Q44578270 | ||
| Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons | Q44747866 | ||
| Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. | Q44750292 | ||
| New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis | Q44915204 | ||
| Decreased brain dopaminergic transporters in HIV-associated dementia patients | Q45023437 | ||
| Cerebral metabolic dysfunction in AIDS: findings in a sample with and without dementia | Q45079034 | ||
| Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. | Q45111041 | ||
| Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. | Q45285935 | ||
| Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance | Q45370440 | ||
| Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains | Q45383832 | ||
| Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco | Q46240579 | ||
| Incident major depression does not affect neuropsychological functioning in HIV-infected men. | Q46707168 | ||
| Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. | Q47724311 | ||
| Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. | Q48063516 | ||
| Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier | Q48230350 | ||
| Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis | Q48413062 | ||
| Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. | Q48586204 | ||
| Paced Auditory Serial Addition Test: adult norms and moderator variables | Q48740353 | ||
| Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia | Q48968501 | ||
| The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. | Q51935722 | ||
| Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. | Q52008026 | ||
| Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. | Q52018425 | ||
| Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. | Q52028216 | ||
| Sociodemographic and psychological variables influencing adherence to antiretroviral therapy | Q59858382 | ||
| Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging | Q70514614 | ||
| Population genetic study of the human dopamine transporter gene (DAT1) | Q71738061 | ||
| Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders | Q71761149 | ||
| Cerebral metabolic change in patients with AIDS: report of a six-month follow-up using positron-emission tomography | Q71936986 | ||
| Neuronal damage of the substantia nigra in HIV-1 infected brains | Q73727349 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 78-91 | |
| P577 | publication date | 2011-11-14 | |
| P1433 | published in | Neuropsychology, Development and Cognition. Section A: Journal of Clinical and Experimental Neuropsychology | Q15762076 |
| P1476 | title | Functional polymorphisms in dopamine-related genes: effect on neurocognitive functioning in HIV+ adults | |
| P478 | volume | 34 |
| Q36345352 | A family history of substance dependence obscures the group differences in brain function associated with HIV-1 and ART. |
| Q36318703 | Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity |
| Q47909466 | Association between genes, stressful childhood events and processing bias in depression vulnerable individuals |
| Q35058518 | Genetic predictor of working memory and prefrontal function in women with HIV. |
| Q26865707 | Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder |
| Q37376944 | HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations |
| Q34001122 | Host genetic factors predisposing to HIV-associated neurocognitive disorder |
| Q37188241 | Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals |
| Q35007339 | Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors |
| Q40241936 | Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. |
| Q34706686 | Neurocognitive function in HIV infected patients on antiretroviral therapy |
| Q59350870 | Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics |
| Q89883581 | The Role of Brain Derived Neurotrophic Factor in HIV-Associated Neurocognitive Disorder: From the Bench-Top to the Bedside |
| Q40426768 | The dopamine-related polymorphisms BDNF, COMT, DRD2, DRD3, and DRD4 are not linked with changes in CSF dopamine levels and frequency of HIV infection |
| Q30410418 | The longitudinal and interactive effects of HIV status, stimulant use, and host genotype upon neurocognitive functioning |
| Q34383112 | Toward a unified biological hypothesis for the BDNF Val66Met-associated memory deficits in humans: a model of impaired dendritic mRNA trafficking. |
Search more.